[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polycystic-ovarian-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polycystic-ovarian-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,108,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642028","comparative-effects-of-neurodynamic-stretch-and-myofascial-pain-release-in-polycystic-ovarian-syndrome-100642028",false,"NCT07645014","Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polycystic Ovarian Syndrome.","Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Dysmenorrhea, Quality Of Sleep And Stress In Polycystic Ovarian Syndrome.","Inclusion Criteria:\n\n* • Age 18-35 years\n\n  * Diagnosed cases of PCOS\n  * Irregular periods until 3 months.\n  * Presence of dysmenorrhea (Check WaLIDD Questionnaire)\n  * BMI\n  * Age of Menarche (13 years)\n\nExclusion Criteria:\n\n* • History of endocrine disorders\n\n  * Endometriosis\n  * Tumour\n  * Any major surgeries\n  * Marital Status (un married)","FEMALE","18 Years","35 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study will be a non-blinded randomized controlled trial, consisting of two groups. Non-probability Convenience sampling will be used to recruit participants who will meet the inclusion criteria. Group allocation will be performed using the sealed envelope method to ensure randomization of participants into experimental and control groups. The sample size will be 38 (19 in each group). Group A will receive neurodynamic stretches while Group B will receive myofascial pain release technique.",[27],"Polycystic Ovarian Syndrome",[29,30,31,32,33],"Dysmenorrhea","Myofascial pain release Neurodynamic stretch","Polycystic ovarian syndrome","Quality of sleep","Stress","RECRUITING","2026-06-08",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2025-10-01",{"date":42,"type":21},"2026-07-01",{"name":44,"class":45},"Riphah International University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100464314","phase-3-comparison-of-the-euploid-rate-of-blastocyst-between-ppos-and-gnrh-antagonist-protocol-in-women-with-pcos-undergoing-pgt-a-100464314","NCT05326087","Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A","A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the PPOS (Progestin-primed Ovarian Stimulation) Protocol and the Gonadotropin-releasing Hormone (GnRH) Antagonist Protocol in Women With PCOS (Polycystic Ovary Syndrome) Undergoing PGT-A (Preimplantation Genetic Testing for Aneuploidy)","Inclusion Criteria:\n\n* Women age between 20 and 37 years.\n* Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and\u002For ovarian volume \\>10 mL on transvaginal ultrasonographic scanning, and\u002For clinical\u002F biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded\n\nExclusion Criteria:\n\n* Presence of a functional ovarian cyst with E2\\>100 pg\u002FmL\n* Endometriosis grade 3 or higher\n* Repeated implantation failure (\\>=4 embryos replaced or \\>=2 blastocysts replaced without success)\n* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)\n* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;\n* Recipient of oocyte donation\n* Presence of hydrosalpinx which is not surgically treated","20 Years","37 Years",{"count":57,"type":21},204,[59],"PHASE3","This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:\n\nAntagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.\n\nPPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.\n\nThe primary outcome is the euploidy rate of blastocysts.",[62,63,27,64],"Preimplantation Genetic Testing","Progestin-primed Ovarian Stimulation","GnRH Antagonist","NOT_YET_RECRUITING","2026-01-29",{"date":68,"type":38},"2026-02-02",{"date":70,"type":21},"2026-06-01",{"date":72,"type":21},"2028-12-01",{"name":74,"class":45},"ShangHai Ji Ai Genetics & IVF Institute",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100505204","clinical-application-of-serum-anti-mllerian-hormone-amh-measurements-100505204","NCT05858307","Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements","Inclusion Criteria:\n\n* Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI\n* Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment\n\nExclusion Criteria:\n\n* Women with age \\\u003C10 or ≥45\n* Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion","10 Years","44 Years",{"count":84,"type":21},300,"OBSERVATIONAL","This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following:\n\n1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS.\n2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI.\n3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment.\n4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment.\n5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.",[88,27,89,90],"Anti-Müllerian Hormone","Premature Ovarian Insufficiency","Fertility Issues",[92,27,89,93,94,95,96,97,98],"Anti-Müllerian hormone","Assisted Reproductive Technology treatment","Predictive value","Reproductive outcomes","AMH","PCOS","POI","2025-03-26",{"date":101,"type":38},"2025-03-27",{"date":103,"type":38},"2022-06-22",{"date":105,"type":21},"2026-12-31",{"name":107,"class":45},"Chinese University of Hong Kong",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100561248","sitagliptin-or-beidougen-capsule-improve-the-pregnancy-outcome-in-patients-with-pcos-100561248","NCT06587698","Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS","Inclusion Criteria:\n\n* Female patients aged 20-40 years who plan to conceive or are infertile in our center.\n\nDiagnosed with PCOS according to the Rotterdam criteria: Diagnosis of PCOS can be made if two out of the following three criteria are met: (1) Oligoovulation or anovulation, (2) Clinical or biochemical signs of hyperandrogenism, (3) Polycystic ovaries on ultrasound examination.\n\nPatients who are regularly followed up at our clinic. No participation in other research projects currently or in the past 3 months.\n\nExclusion Criteria:\n\nExclusion criteria (any of the following criteria met will result in exclusion):\n\nPregnant, lactating, or postmenopausal women. Taking weight loss medications or undergoing weight loss surgery in the past 3 months or currently.\n\nFood allergies. Other diseases that may cause hyperandrogenism or ovulation abnormalities (e.g., Cushing's syndrome, non-classical congenital adrenal hyperplasia, tumors secreting androgens in the ovaries or adrenal glands, functional hypothalamic amenorrhea, thyroid diseases, hyperprolactinemia, premature ovarian insufficiency, etc.).\n\nUse of insulin, hypoglycemic drugs, or beta-blockers in the past 3 months. Patients with chronic diseases such as hypertension, gout, hyperuricemia, diabetes, etc., requiring regular medication.\n\nUse of glucocorticoids, anti-androgenic drugs, oral contraceptives, ovulation-inducing drugs, weight loss drugs, or other medications affecting hormone levels, appetite, and carbohydrate metabolism in the past 2 months.\n\nPatients with liver cirrhosis or various severe liver diseases (alanine aminotransferase and\u002For aspartate aminotransferase exceeding 3 times the upper limit of normal), patients with abnormal renal function (serum creatinine exceeding the upper limit of normal), patients with kidney disease or other diseases requiring control of protein intake.\n\nPatients currently or previously with severe cardiovascular and cerebrovascular diseases that may interfere with the normal conduct of the trial (such as heart failure, myocardial infarction, cerebral infarction, acute myocarditis, severe arrhythmias, patients undergoing interventional therapy, etc.).\n\nPatients currently with severe gastrointestinal diseases such as gastrointestinal ulcer bleeding, chronic diarrhea, or who have undergone gastrointestinal resection surgery, which may affect nutrient absorption.\n\nPatients with infectious diseases such as hepatitis B e antigen-positive, active pulmonary tuberculosis, or HIV.\n\nCancer patients or those who have received radiation and chemotherapy within the past five years.\n\nPatients with any psychological or psychiatric disorders requiring medication, including epilepsy patients or those undergoing antiepileptic treatment, patients using antidepressants, etc.\n\nDaily alcohol consumption exceeding 15g. Smoking habit\n\n\\-","40 Years",{"count":84,"type":21},[24],"This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research",[27],"2024-09-04",{"date":121,"type":38},"2024-09-19",{"date":123,"type":38},"2024-08-21",{"date":125,"type":21},"2029-07-01",{"name":127,"class":45},"Peking University Third Hospital",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":136,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":139,"conditions":140,"keywords":148,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":46},"100178744","genetics-of-reproductive-disorders-including-kallmann-syndrome-and-cleft-lip-andor-palate-100178744","NCT01601171","Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and\u002For Palate","The Genetics of Neuroendocrine Reproductive Disorders and of the Cleft Lip and\u002For Palate","Inclusion Criteria:(any of the following conditions)\n\n* hypogonadotropic hypogonadism\n* Kallmann syndrome\n* adult-onset hypogonadotropic hypogonadism\n* hypothalamic amenorrhea\n* polycystic ovarian syndrome\n* primary gonadal failure\n* precocious puberty\n* cleft lip\u002Fpalate\n* family members of the above groups\n\nExclusion Criteria:\n\n* acute illness\u002Fhospitalization\n* pituitary tumors\n* iron overload (hemochromatosis)\n* infiltrative diseases (sarcoidosis)\n* chronic alcohol abuse\n* illicit drug use\n* anabolic steroid abuse",true,"ALL",{"count":138,"type":21},2000,"The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and\u002For palate.",[141,142,143,27,144,145,146,147],"Kallmann Syndrome","Hypogonadotropic Hypogonadism","Hypothalamic Amenorrhea","Precocious Puberty","Cleft Lip and Palate","Cleft Palate","Cleft Lip",[149,150,151,152,153,154,155,156],"GnRH deficiency","hypogonadism","anosmia","infertility","cleft lip","cleft palate","cryptorchidism","microphallus","2022-06-17",{"date":159,"type":38},"2022-06-21",{"date":161,"type":4},"2012-03",{"date":163,"type":21},"2030-03",{"name":165,"class":45},"Centre Hospitalier Universitaire Vaudois"]